Role of substance P in the cardiovascular system
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
26706184
DOI
10.1016/j.npep.2015.12.005
PII: S0143-4179(15)00225-5
Knihovny.cz E-zdroje
- Klíčová slova
- Antagonist, Cardiovascular regulation, NK1 receptor, Substance P,
- MeSH
- antagonisté neurokininových receptorů typu 1 farmakologie MeSH
- ischemická choroba srdeční patofyziologie MeSH
- ischemie mozku patofyziologie MeSH
- kardiovaskulární fyziologické jevy * MeSH
- lidé MeSH
- mozek fyziologie MeSH
- nemoci srdce patofyziologie MeSH
- receptory neurokininu-1 fyziologie MeSH
- signální transdukce MeSH
- substance P biosyntéza metabolismus fyziologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- antagonisté neurokininových receptorů typu 1 MeSH
- receptory neurokininu-1 MeSH
- substance P MeSH
This article provides an overview of the structure and function of substance P signalling system and its involvement in the cardiovascular regulation. Substance P is an undecapeptide originating from TAC1 gen and belonging to the tachykinin family. The biological actions of substance P are mainly mediated through neurokinin receptor 1 since substance P is the ligand with the highest affinity to neurokinin receptor 1. Substance P is widely distributed within the central and peripheral nervous systems as well as in the cardiovascular system. Substance P is involved in the regulation of heart frequency, blood pressure and in the stretching of vessels. Substance P plays an important role in ischemia and reperfusion and cardiovascular response to stress. Additionally, it has been also implicated in angiogenesis, pain transmission and inflammation. The substance P/neurokinin receptor 1 receptor system is involved in the molecular bases of many human pathological processes. Antagonists of neurokinin receptor 1 receptor could provide clinical solutions for a variety of diseases. Neurokinin receptor 1 antagonists are already used in the prevention of chemotherapy induced nausea and vomiting.
Citace poskytuje Crossref.org